{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T03:26:02Z","timestamp":1793676362561,"version":"4.5.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s00259-026-08194-6","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T01:19:24Z","timestamp":1789953564000},"page":"8661-8674","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeted alpha therapy for recurrent high-grade glioma with [\u00b2\u00b2\u2075Ac]-PSMA: a new theranostic approach"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0954-5707","authenticated-orcid":false,"given":"Haluk Burcak","family":"Sayman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1758-0542","authenticated-orcid":false,"given":"Omer","family":"Aras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6826-9311","authenticated-orcid":false,"given":"Muhammed Veysel","family":"Hekim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0626-5945","authenticated-orcid":false,"given":"Kerem","family":"Sa\u011flam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5625-9749","authenticated-orcid":false,"given":"Elife","family":"Akg\u00fcn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4764-9419","authenticated-orcid":false,"given":"Fazilet \u00d6ner","family":"Din\u00e7ba\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"key":"8194_CR1","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987\u201396. https:\/\/doi.org\/10.1056\/NEJMoa043330.","journal-title":"N Engl J Med"},{"key":"8194_CR2","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","volume":"10","author":"R Stupp","year":"2009","unstructured":"Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459\u201366. https:\/\/doi.org\/10.1016\/S1470-2045(09)70025-7.","journal-title":"Lancet Oncol"},{"key":"8194_CR3","doi-asserted-by":"publisher","first-page":"3838","DOI":"10.1200\/JCO.2010.30.0582","volume":"28","author":"JK Park","year":"2010","unstructured":"Park JK, Hodges T, Arko L, et al. Scale to predict survival after surgery for recurrent glioblastoma multiforme. J Clin Oncol. 2010;28:3838\u201343. https:\/\/doi.org\/10.1200\/JCO.2010.30.0582.","journal-title":"J Clin Oncol"},{"key":"8194_CR4","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.4103\/ajns.AJNS_235_16","volume":"13","author":"F Salle","year":"2018","unstructured":"Salle F, Lahiani W, Spagnuolo E, Palfi S. Adverse event with the use of carmustine wafers and postoperative radiochemotherapy for the treatment of high-grade glioma. Asian J Neurosurg. 2018;13:1171\u20134. https:\/\/doi.org\/10.4103\/ajns.AJNS_235_16.","journal-title":"Asian J Neurosurg"},{"key":"8194_CR5","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.ccell.2014.10.006","volume":"26","author":"RK Jain","year":"2014","unstructured":"Jain RK. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell. 2014;26:605\u201322. https:\/\/doi.org\/10.1016\/j.ccell.2014.10.006.","journal-title":"Cancer Cell"},{"key":"8194_CR6","doi-asserted-by":"publisher","first-page":"1085245","DOI":"10.3389\/fmed.2022.1085245","volume":"9","author":"J Kunikowska","year":"2022","unstructured":"Kunikowska J, Morgenstern A, Pe\u0142ka K, Bruchertseifer F, Kr\u00f3licki L. Targeted alpha therapy for glioblastoma. Front Med (Lausanne). 2022;9:1085245. https:\/\/doi.org\/10.3389\/fmed.2022.1085245.","journal-title":"Front Med (Lausanne)"},{"key":"8194_CR7","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1001\/jamaoncol.2018.4044","volume":"4","author":"C Parker","year":"2018","unstructured":"Parker C, Lewington V, Shore N, et al. Targeted alpha therapy, an emerging class of cancer agents. JAMA Oncol. 2018;4:1765\u201372. https:\/\/doi.org\/10.1001\/jamaoncol.2018.4044.","journal-title":"JAMA Oncol"},{"key":"8194_CR8","doi-asserted-by":"publisher","first-page":"685","DOI":"10.2967\/jnumed.122.265353","volume":"64","author":"B Feuerecker","year":"2023","unstructured":"Feuerecker B, Kratochwil C, Ahmadzadehfar H, et al. Clinical translation of targeted \u03b1-therapy: an evolution or a revolution? J Nucl Med. 2023;64:685\u201392. https:\/\/doi.org\/10.2967\/jnumed.122.265353.","journal-title":"J Nucl Med"},{"key":"8194_CR9","doi-asserted-by":"publisher","first-page":"200","DOI":"10.2174\/1874471011666180502104524","volume":"11","author":"A Morgenstern","year":"2018","unstructured":"Morgenstern A, Apostolidis C, Kratochwil C, Sathekge M, Krolicki L, Bruchertseifer F. An overview of targeted alpha therapy with 225 actinium and 213 bismuth. Curr Radiopharm. 2018;11:200\u20138. https:\/\/doi.org\/10.2174\/1874471011666180502104524.","journal-title":"Curr Radiopharm"},{"key":"8194_CR10","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1053\/j.semnuclmed.2019.11.004","volume":"50","author":"L Kr\u00f3licki","year":"2020","unstructured":"Kr\u00f3licki L, Kunikowska J, Bruchertseifer F, et al. 225Ac- and 213Bi-substance P analogues for glioma therapy. Semin Nucl Med. 2020;50:141\u201351. https:\/\/doi.org\/10.1053\/j.semnuclmed.2019.11.004.","journal-title":"Semin Nucl Med"},{"key":"8194_CR11","doi-asserted-by":"publisher","first-page":"30","DOI":"10.2967\/jnumed.107.046938","volume":"49","author":"MR Zalutsky","year":"2008","unstructured":"Zalutsky MR, Reardon DA, Akabani G, et al. Clinical experience with \u03b1-particle\u2013emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. J Nucl Med. 2008;49:30\u20138. https:\/\/doi.org\/10.2967\/jnumed.107.046938.","journal-title":"J Nucl Med"},{"key":"8194_CR12","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.2967\/jnumed.120.248443","volume":"62","author":"AC Eder","year":"2021","unstructured":"Eder AC, Sch\u00e4fer M, Schmidt J, et al. Rational linker design to accelerate excretion and reduce background uptake of peptidomimetic PSMA-targeting hybrid molecules. J Nucl Med. 2021;62:1461\u20137. https:\/\/doi.org\/10.2967\/jnumed.120.248443.","journal-title":"J Nucl Med"},{"key":"8194_CR13","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1148\/rg.2018170108","volume":"38","author":"MS Hofman","year":"2018","unstructured":"Hofman MS, Hicks RJ, Maurer T, Eiber M. Prostate-specific membrane antigen PET: clinical utility in prostate cancer, normal patterns, pearls, and pitfalls. Radiographics. 2018;38:200\u201317. https:\/\/doi.org\/10.1148\/rg.2018170108.","journal-title":"Radiographics"},{"key":"8194_CR14","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, et al. Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385:1091\u2013103. https:\/\/doi.org\/10.1056\/NEJMoa2107322.","journal-title":"N Engl J Med"},{"key":"8194_CR15","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1111\/apm.12195","volume":"122","author":"AG Wernicke","year":"2014","unstructured":"Wernicke AG, Varma S, Greenwood EA, et al. Prostate-specific membrane antigen expression in tumor-associated vasculature of breast cancers. APMIS. 2014;122:482\u20139. https:\/\/doi.org\/10.1111\/apm.12195.","journal-title":"APMIS"},{"key":"8194_CR16","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/s41598-021-04613-w","volume":"12","author":"J Kunikowska","year":"2022","unstructured":"Kunikowska J, Czepczy\u0144ski R, Pawlak D, et al. Expression of glutamate carboxypeptidase II in the glial tumor recurrence evaluated in vivo using radionuclide imaging. Sci Rep. 2022;12:652. https:\/\/doi.org\/10.1038\/s41598-021-04613-w.","journal-title":"Sci Rep"},{"key":"8194_CR17","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1055\/s-0045-1804439","volume":"64","author":"M Mair","year":"2025","unstructured":"Mair M, Holzgreve A, Delker A, et al. Uptake patterns of PSMA PET in brain tumors: comparative analysis of [68Ga]Ga-PSMA-11 or [18F]PSMA-1007 PET with [18F]FET PET and contrast-enhanced MRI. Nuklearmedizin. 2025;64:101\u20132. https:\/\/doi.org\/10.1055\/s-0045-1804439.","journal-title":"Nuklearmedizin"},{"key":"8194_CR18","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","volume":"28","author":"PY Wen","year":"2010","unstructured":"Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: Response Assessment in Neuro-Oncology Working Group. J Clin Oncol. 2010;28:1963\u201372. https:\/\/doi.org\/10.1200\/JCO.2009.26.3541.","journal-title":"J Clin Oncol"},{"key":"8194_CR19","doi-asserted-by":"publisher","first-page":"15701","DOI":"10.3390\/ijms242115701","volume":"24","author":"L Krolicki","year":"2023","unstructured":"Krolicki L, Kunikowska J, Cordier D, et al. Long-term tumor control following targeted alpha therapy (TAT) of low-grade gliomas (LGGs): a new treatment paradigm? Int J Mol Sci. 2023;24:15701. https:\/\/doi.org\/10.3390\/ijms242115701.","journal-title":"Int J Mol Sci"},{"key":"8194_CR20","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1111\/cbdd.13199","volume":"92","author":"A Majkowska-Pilip","year":"2018","unstructured":"Majkowska-Pilip A, Rius M, Bruchertseifer F, et al. In vitro evaluation of 225Ac-DOTA-substance P for targeted alpha therapy of glioblastoma multiforme. Chem Biol Drug Des. 2018;92:1344\u201356. https:\/\/doi.org\/10.1111\/cbdd.13199.","journal-title":"Chem Biol Drug Des"},{"key":"8194_CR21","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.5858\/arpa.2010-0740-OA","volume":"135","author":"AG Wernicke","year":"2011","unstructured":"Wernicke AG, Edgar MA, Lavi E, et al. Prostate-specific membrane antigen as a potential novel vascular target for treatment of glioblastoma multiforme. Arch Pathol Lab Med. 2011;135:1486\u20139. https:\/\/doi.org\/10.5858\/arpa.2010-0740-OA.","journal-title":"Arch Pathol Lab Med"},{"issue":"8","key":"8194_CR22","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1089\/cbr.2018.2494","volume":"33","author":"NA Thiele","year":"2018","unstructured":"Thiele NA, Wilson JJ. Actinium-225 for targeted \u03b1 therapy: coordination chemistry and current chelation approaches. Cancer Biother Radiopharm. 2018;33(8):336\u201348. https:\/\/doi.org\/10.1089\/cbr.2018.2494.","journal-title":"Cancer Biother Radiopharm"},{"issue":"1","key":"8194_CR23","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s41181-022-00174-z","volume":"7","author":"D Castillo Seoane","year":"2022","unstructured":"Castillo Seoane D, De Saint-Hubert M, Ahenkorah S, Saldarriaga Vargas C, Ooms M, Struelens L, Koole M. Gamma counting protocols for the accurate quantification of \u00b2\u00b2\u2075Ac and \u00b2\u00b9\u00b3Bi without the need for a secular equilibrium between parent and gamma-emitting daughter. EJNMMI Radiopharm Chem. 2022;7(1):28. https:\/\/doi.org\/10.1186\/s41181-022-00174-z.","journal-title":"EJNMMI Radiopharm Chem"},{"key":"8194_CR24","doi-asserted-by":"publisher","first-page":"100004","DOI":"10.1016\/j.craph.2025.100004","volume":"19","author":"J Crudo","year":"2026","unstructured":"Crudo J, Duatti A. Open problems for the preparation and quality control of Ac-225 radiopharmaceuticals. Curr Radiopharm. 2026;19:100004. https:\/\/doi.org\/10.1016\/j.craph.2025.100004.","journal-title":"Curr Radiopharm"},{"key":"8194_CR25","doi-asserted-by":"publisher","first-page":"108990","DOI":"10.1016\/j.nucmedbio.2024.108990","volume":"142\u2013143","author":"M Tosato","year":"2025","unstructured":"Tosato M, Favaretto C, Kleynhans J, et al. Alpha Atlas: mapping global production of \u03b1-emitting radionuclides for targeted alpha therapy. Nucl Med Biol. 2025;142\u2013143:108990. https:\/\/doi.org\/10.1016\/j.nucmedbio.2024.108990.","journal-title":"Nucl Med Biol"},{"issue":"14","key":"8194_CR26","doi-asserted-by":"publisher","first-page":"11626","DOI":"10.3390\/ijms241411626","volume":"24","author":"A Jang","year":"2023","unstructured":"Jang A, Kendi AT, Johnson GB, Halfdanarson TR, Sartor O. Targeted alpha-particle therapy: a review of current trials. Int J Mol Sci. 2023;24(14):11626. https:\/\/doi.org\/10.3390\/ijms241411626.","journal-title":"Int J Mol Sci"},{"issue":"12","key":"8194_CR27","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.2967\/jnumed.125.269744","volume":"66","author":"A Wurzer","year":"2025","unstructured":"Wurzer A, Sun B, Saleh S, et al. [\u00b2\u00b2\u2075Ac]Ac-PSMA I&T: a preclinical investigation on the fate of decay nuclides and their influence on dosimetry of salivary glands and kidneys. J Nucl Med. 2025;66(12):1964\u20139. https:\/\/doi.org\/10.2967\/jnumed.125.269744.","journal-title":"J Nucl Med"},{"key":"8194_CR28","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s00259-025-07427-4","volume":"53","author":"S Zitzmann-Kolbe","year":"2025","unstructured":"Zitzmann-Kolbe S, Remde Y, Moen I, et al. Biodistribution of free Francium-221 and Bismuth-213 in tumour-bearing SCID mice after successful development of an Actinium-225\/Francium-221 radionuclide generator set-up. Eur J Nucl Med Mol Imaging. 2025;53:633\u201346. https:\/\/doi.org\/10.1007\/s00259-025-07427-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"8194_CR29","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.7150\/thno.96403","volume":"14","author":"AP Bidkar","year":"2024","unstructured":"Bidkar AP, Zerefa L, Yadav S, VanBrocklin HF, Flavell RR. Actinium-225 targeted alpha particle therapy for prostate cancer. Theranostics. 2024;14(7):2969\u201392. https:\/\/doi.org\/10.7150\/thno.96403.","journal-title":"Theranostics"},{"issue":"1","key":"8194_CR30","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s12951-024-02520-6","volume":"22","author":"M Toro-Gonz\u00e1lez","year":"2024","unstructured":"Toro-Gonz\u00e1lez M, Akingbesote N, Bible A, et al. Development of \u00b2\u00b2\u2075Ac-doped biocompatible nanoparticles for targeted alpha therapy. J Nanobiotechnol. 2024;22(1):306. https:\/\/doi.org\/10.1186\/s12951-024-02520-6.","journal-title":"J Nanobiotechnol"},{"issue":"2","key":"8194_CR31","first-page":"253","volume":"45","author":"S Sofou","year":"2004","unstructured":"Sofou S, et al. Engineered liposomes for potential \u03b1-particle therapy of metastatic cancer. J Nucl Med. 2004;45(2):253\u201360.","journal-title":"J Nucl Med"},{"issue":"6","key":"8194_CR32","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1021\/bc070075t","volume":"18","author":"S Sofou","year":"2007","unstructured":"Sofou S, Kappel BJ, Jaggi JS, McDevitt MR, Scheinberg DA, Sgouros G. Enhanced retention of the \u03b1-particle emitting daughters of actinium-225 by liposome carriers. Bioconjug Chem. 2007;18(6):2061\u20137. https:\/\/doi.org\/10.1021\/bc070075t.","journal-title":"Bioconjug Chem"},{"key":"8194_CR33","doi-asserted-by":"publisher","first-page":"11671","DOI":"10.1038\/s41598-019-48298-8","volume":"9","author":"RM de Kruijff","year":"2019","unstructured":"de Kruijff RM, Raav\u00e9 R, Kip A, et al. The in vivo fate of \u00b2\u00b2\u2075Ac daughter nuclides using polymersomes as a model carrier. Sci Rep. 2019;9:11671. https:\/\/doi.org\/10.1038\/s41598-019-48298-8.","journal-title":"Sci Rep"},{"key":"8194_CR34","doi-asserted-by":"publisher","first-page":"108973","DOI":"10.1016\/j.nucmedbio.2024.108973","volume":"140\u2013141","author":"M Sakm\u00e1r","year":"2025","unstructured":"Sakm\u00e1r M, Kozempel J, Ku\u010dka J, et al. In vitro and in vivo study of \u00b2\u00b2\u00b9Fr and \u00b2\u00b9\u00b3Bi progeny release from the \u00b2\u00b2\u2075Ac-labelled TiO\u2082 nanoparticles. Nucl Med Biol. 2025;140\u2013141:108973. https:\/\/doi.org\/10.1016\/j.nucmedbio.2024.108973.","journal-title":"Nucl Med Biol"},{"key":"8194_CR35","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.3390\/diagnostics12071665","volume":"12","author":"B Muoio","year":"2022","unstructured":"Muoio B, Albano D, Dondi F, et al. Diagnostic accuracy of PET\/CT or PET\/MRI using PSMA-targeting radiopharmaceuticals in high-grade gliomas: a systematic review and a bivariate meta-analysis. Diagnostics. 2022;12:1665. https:\/\/doi.org\/10.3390\/diagnostics12071665.","journal-title":"Diagnostics"},{"key":"8194_CR36","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.2967\/jnumed.123.265738","volume":"64","author":"SAM van Lith","year":"2023","unstructured":"van Lith SAM, Pruis IJ, Tolboom N, et al. PET imaging and protein expression of prostate-specific membrane antigen in glioblastoma: a multicenter inventory study. J Nucl Med. 2023;64:1526\u201331. https:\/\/doi.org\/10.2967\/jnumed.123.265738.","journal-title":"J Nucl Med"},{"key":"8194_CR37","doi-asserted-by":"publisher","first-page":"6768","DOI":"10.7150\/thno.101922","volume":"14","author":"M Yang","year":"2024","unstructured":"Yang M, Wang L, Qin S, et al. Role of damaged mitochondrial transfer in alpha-particle generator \u00b2\u00b9\u00b2Pb radiation-induced bystander effect. Theranostics. 2024;14:6768\u201382. https:\/\/doi.org\/10.7150\/thno.101922.","journal-title":"Theranostics"},{"key":"8194_CR38","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.2967\/jnumed.117.191395","volume":"58","author":"C Kratochwil","year":"2017","unstructured":"Kratochwil C, Bruchertseifer F, Rathke H, et al. Targeted \u03b1-therapy of metastatic castration-resistant prostate cancer with \u00b2\u00b2\u2075Ac-PSMA-617: dosimetry estimate and empiric dose finding. J Nucl Med. 2017;58:1624\u201331. https:\/\/doi.org\/10.2967\/jnumed.117.191395.","journal-title":"J Nucl Med"},{"key":"8194_CR39","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s00259-019-04612-0","volume":"47","author":"F Khreish","year":"2020","unstructured":"Khreish F, Ebert N, Ries M, et al. \u00b2\u00b2\u2075Ac-PSMA-617\/\u00b9\u2077\u2077Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience. Eur J Nucl Med Mol Imaging. 2020;47:721\u20138. https:\/\/doi.org\/10.1007\/s00259-019-04612-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8194_CR40","doi-asserted-by":"publisher","first-page":"4050","DOI":"10.7150\/thno.56211","volume":"11","author":"F Rosar","year":"2021","unstructured":"Rosar F, Hau F, Bartholom\u00e4 M, et al. Molecular imaging and biochemical response assessment after a single cycle of [\u00b2\u00b2\u2075Ac]Ac-PSMA-617\/[\u00b9\u2077\u2077Lu]Lu-PSMA-617 tandem therapy in mCRPC patients who have progressed on [\u00b9\u2077\u2077Lu]Lu-PSMA-617 monotherapy. Theranostics. 2021;11:4050\u201360. https:\/\/doi.org\/10.7150\/thno.56211.","journal-title":"Theranostics"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08194-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-08194-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08194-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T02:29:57Z","timestamp":1793672997000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-08194-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":40,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["8194"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-08194-6","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,21]]},"assertion":[{"value":"12 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Institutional Ethics Committee (Document No: 83045809-604.01.02-166583), conducted in accordance with the Declaration of Helsinki and informed verbal and written consent form was obtained from all patients.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors affirm that all individual participants provided informed consent for publication of their clinical data and related imaging findings included in this manuscript.","order":3,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}